The chemotherapy of head and neck cancer

Acta Oto-Rhino-Laryngologica Belgica

Volumn 53, Issue 3, 1999, Pages 247-252

  De Mulder, P H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 FU; Cisplatin; Docetaxel; Head and neck cancer

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; HEAD AND NECK CANCER; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; TAXOIDS;

EID: 0032715015     PISSN: 00016497     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. WINGO P. A., TONG T., BOLDEN S. Cancer Statistics CA 45 : 8-30, 1995.
2. VOKES E. E., WEICHSELBAUM R. R., LIPPMAN S. et al. Head and neck cancer. N. Engl. J. Med., 328 : 184-194, 1993.
3. VOKES E. E. Head and Neck Cancer. In : The chemotherapy source book. M. PERRY (ed.), Williams and Willkins, Maryland, pp. 1083-1101, 1997.
4. CLAVEL M., VERMORKEN J. B., COGNETTI F. et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck : a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol., 5 : 521-526, 1994.
5. JACOBS C., LYNMAN G., VELEZ-GARCIA E. et al. A phase III randomized study comparing cisplatin and flourouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol., 10 : 257-263, 1992.
6. FORASTIERE A. A., METCH B., SCHULLER D. E. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck : a Southwest Oncology Group study. J. Clin. Oncol., 10 : 1245-1251, 1992.
7. Liverpool Head and Neck Oncology Group. A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end-stage squamous cell carcinoma of the head and neck. Br. J. Cancer, 61 : 311-315, 1990.
8. VOKES E. E., WECHELBAUM R. R. Combined modality therapy for head and neck cancer. Principals and Practice of Oncology Update, 6 : 1-2, 1993.
9. LEFEBVRE J. L., CHEVALIER D., LUBORNSKI B. et al. Larynx preservation in hypopharynx and lateral epirynx cancer : preliminary results of EORTC randomized phase III trial 2891. J. Natl. Cancer Inst., 88 : 890-98, 1996.
10. VA Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med., 324 : 1685-1690, 1991.
11. POSNER M., DREYFUSS A., CLARK J. et al. Docetaxel for advanced, incurable squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol., 15 : 311 (abstr 0996), 1996.
12. CATIMEL G., VERWEIJ J., MATTIJSSEN V. et al. Docetaxel (Taxotere) : an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann. Oncol., 5 : 533-537, 1994.
13. COUTEAU C., LEYVRAZ S., OULID-AISSA D. et al. A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck. Proc. Am. Soc. Clin. Oncol., 15 : 315 (abstr 889), 1996.
14. SCHOFFSKI P., WANDERS J., CATIMEL G. et al. A promising regimen for the treatment of squamous cell carcinoma of the head and neck. Docetaxel and cisplatin. Ann. Oncol., 7 : 79 (suppl 5) (abstr 373P), 1998.
15. JANINIS J., PAPADAKOU G., PANAGOS C. et al. A phase II study of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) in patients with adavanced squamous cell carcinoma of the head and neck (SCCHN) and nasopharangeal carcinoma (NC). Am. Soc. Clin. Oncol., 16 : 402a (abstr 1436), 1997.
16. POSNER M., NORRIS O., COLEVAS A. et al. Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPLF) for curable, locally advanced squamous cell cancer of the head and neck (SCCHN). Am. Soc. Clin. Oncol., 16 : 387a (abstr 1380), 1997.
17. COLVELAS D. A., BUSSE P. M., NORRIS C. M. et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovarin for squamous cell carcinoma of the head and neck : a phase I/II trial. J. Clin. Oncol., 16(4) : 1331-1339, 1998.
18. FORASTIERE A., GLISSON B., MURPHY B. et al. A phase II study of docetaxel and cisplatin in patients with locally advanced, recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), not curable by standard therapy. Proc. Am. Soc. Clin. Oncol., 17 : 399a (Abstr 1540), 1998.
19. KIENZER H. R., SCHWEIGER J., BAUR M. et al. Docetaxel (D) / cisplatin (P) as firt-line therapy in head and neck cancer (HNC). Proc. Am. Soc. Clin. Oncol., 17 : 406a (Abstr 1566), 1998.
20. TUBIANA-MATHIEU N., MERROUCHE Y., CUPISSOL D. et al. A phase II study of docetaxel (Taxotere) (TXT) in metastatic or recurrent squamous cell carcinoma (SCC) of the head and neck. Proc. Am. Soc. Clin. Oncol., 17 : 412a (Abstr 1587), 1998.
21. ADELSTEIN D. J. Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer. Curr. Opin. Oncol., 10 (3) : 213-218, 1998.